Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
beta-caryophyllene oxide is a naturally occurring bicyclic sesquiterpene oxide found in essential oils of many plants and is the oxidized derivative of beta-caryophyllene. It exhibits **anticancer**, **antioxidant**, **anti-inflammatory**, **antifungal**, **antibacterial**, and **antiviral** activities[2][3]. Mechanistically, it is a strong inhibitor of **cytochrome P450 3A (CYP3A)** enzymes, modulates signaling pathways involved in tumor cell survival and proliferation (including inhibition of PI3K/AKT/mTOR/S6K1), induces apoptosis, reduces cancer cell metastasis and angiogenesis, and upregulates tumor suppressors such as p53 and p21[3]. It is also noted for use in flavoring and fragrances, and is present in GRAS lists for food safety[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on beta-caryophyllene oxide.